Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD).Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at th...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2020.00104/full |
id |
doaj-256c2dfcaed34228be75ded0664750f6 |
---|---|
record_format |
Article |
spelling |
doaj-256c2dfcaed34228be75ded0664750f62020-11-25T03:12:40ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-07-01710.3389/fcvm.2020.00104532843Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic DysfunctionSergiy M. Koval0Iryna O. Snihurska1Kostiantyn O. Yushko2Olga V. Mysnychenko3Marina Yu. Penkova4Olga M. Lytvynova5Alexander E. Berezin6Vadym S. Lytvynov7Department of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Laboratory Diagnostics, National University of Pharmacy, Kharkiv, UkraineInternal Medicine Department, Zaporizhia State Medical University, Zaporizhzhia, UkraineDepartment of Therapy, Rheumatology and Clinical Pharmacology, Kharkiv Medical Academy of Postgraduate Education (KhMAPE), Kharkiv, UkraineAim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD).Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA).Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively).Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD.https://www.frontiersin.org/article/10.3389/fcvm.2020.00104/fullarterial hypertensionhypertensive heart diseasemicroRNA-133aleft ventricular diastolic dysfunctionepigenetics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sergiy M. Koval Iryna O. Snihurska Kostiantyn O. Yushko Olga V. Mysnychenko Marina Yu. Penkova Olga M. Lytvynova Alexander E. Berezin Vadym S. Lytvynov |
spellingShingle |
Sergiy M. Koval Iryna O. Snihurska Kostiantyn O. Yushko Olga V. Mysnychenko Marina Yu. Penkova Olga M. Lytvynova Alexander E. Berezin Vadym S. Lytvynov Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction Frontiers in Cardiovascular Medicine arterial hypertension hypertensive heart disease microRNA-133a left ventricular diastolic dysfunction epigenetics |
author_facet |
Sergiy M. Koval Iryna O. Snihurska Kostiantyn O. Yushko Olga V. Mysnychenko Marina Yu. Penkova Olga M. Lytvynova Alexander E. Berezin Vadym S. Lytvynov |
author_sort |
Sergiy M. Koval |
title |
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_short |
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_full |
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_fullStr |
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_full_unstemmed |
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_sort |
circulating microrna-133a in patients with arterial hypertension, hypertensive heart disease, and left ventricular diastolic dysfunction |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cardiovascular Medicine |
issn |
2297-055X |
publishDate |
2020-07-01 |
description |
Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD).Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA).Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively).Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD. |
topic |
arterial hypertension hypertensive heart disease microRNA-133a left ventricular diastolic dysfunction epigenetics |
url |
https://www.frontiersin.org/article/10.3389/fcvm.2020.00104/full |
work_keys_str_mv |
AT sergiymkoval circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT irynaosnihurska circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT kostiantynoyushko circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT olgavmysnychenko circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT marinayupenkova circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT olgamlytvynova circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT alexandereberezin circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT vadymslytvynov circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction |
_version_ |
1724649150725750784 |